Abstract 651: Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models
Sugawara, Tatsuo, NGuyen, Holly, Corey, Eva, Nevedomskaya, Ekaterina, Politz, Oliver, Mumberg, Dominik, Haendler, Bernard
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
Abstract 4691: Identification and characterization of BRPF1 bromodomain inhibitors
Haendler, Bernard, Bouché, Léa, Siegel, Stephan, Fernandez-Montalvan, Amaury E., Sugawara, Tatsuo, Meier, Julia, Knapp, Stefan, Gamble, Vicki
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article
Abstract B065: Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer
Heller, Simon, Sugawara, Tatsuo, Nevedomskaya, Ekaterina, Baumgart, Simon J., Nguyen, Holly, Corey, Eva, Böhme, Annika, von Ahsen, Oliver, Politz, Oliver, Haendler, Bernard
Published in Cancer research (Chicago, Ill.) (02.06.2023)
Published in Cancer research (Chicago, Ill.) (02.06.2023)
Get full text
Journal Article
BATTERY PACK
WATABIKI YOSHITAKA, SUGAWARA TATSUO, KOJIMA KAZUNORI, IRIE AKIRA, AOKI SADAYUKI, KUBOTA OSAMU
Year of Publication 04.01.2022
Get full text
Year of Publication 04.01.2022
Patent
Abstract 980: BAY-299, a novel chemical probe for in-depth analysis of the function of the bromodomain proteins BRPF2 and TAF1
Bouche, Lea, Christ, Clara D., Siegel, Stephan, Tallant, Cynthia, Fernández-Montalván, Amaury E., Huber, Kilian V., Pütter, Verra, Müller, Susanne, Fedorov, Oleg, Laak, Antonius ter, Sugawara, Tatsuo, Stöckigt, Detlef, Meier, Julia, Holton, Simon J., Hartung, Ingo V., Haendler, Bernard
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article
Abstract 4703: The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models
Haendler, Bernard, Gelato, Kathy A., Schöckel, Laura, Sugawara, Tatsuo, Lejeune, Pascale, Ellinger-Ziegelbauer, Heidrun, Fernandez-Montalvan, Amaury E., Holton, Simon, Siegel, Stephan, Heroult, Melanie, Walter, Annette, Ince, Stuart, Ocker, Matthias
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article
BATTERY PACK
WATAHIKI Yoshitaka, OJIMA Kazunori, SUGAWARA Tatsuo, KUBOTA Osamu, AOKI Sadayuki, IRIE Akira
Year of Publication 02.04.2020
Get full text
Year of Publication 02.04.2020
Patent
Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models
Lejeune, Pascale, Sugawara, Tatsuo, Gelato, Kathy A., Ellinger-Ziegelbauer, Heidrun, Fernandez-Montalvan, Amaury E., Schmees, Norbert, Siegel, Stephan, Weinmann, Hilmar, Gekeler, Volker, Walter, Annette O., Ocker, Matthias, Ince, Stuart, Haendler, Bernard
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article
Abstract 1321: Castration-resistant prostate cancer: BAY 1024767 blocks function of mutated androgen receptor
Haendler, Bernard, Sugawara, Tatsuo, Lejeune, Pascale, Koehr, Silke, Faus, Hortensia, Busemann, Matthias, Cleve, Arwed, Luecking, Ulrich, von Nussbaum, Franz, Brands, Michael, Mumberg, Dominik
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Published in Cancer research (Chicago, Ill.) (15.04.2013)
Get full text
Journal Article